Phase 4 Study - Mucinex D as Adjunct Therapy

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to evaluate the safety and efficacy of Mucinex D tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with acute respiratory infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Adams Respiratory Therapeutics
• Treatments: Chlorpheniramine, phenylpropanolamine drug combination; Ephedrine; Guaifenesin; Phenylpropanolamine; Pseudoephedrine

Criteria

Inclusion Criteria:

• Ages Eligible for Study: 18 to 75 years,

• Genders Eligible for Study: Both

• Adult patients presenting at the physician's office with symptoms diagnostic for acute respiratory infection, such as bronchitis or rhinosinusitis; with a clinical diagnosis of acute respiratory infection, meeting the physician's usual diagnostic criteria in practice for prescription of oral antibiotics.

• The investigator will evaluate patients on a total of seven criteria for inclusion.

Exclusion Criteria:

• Have chronic, recurring respiratory signs and symptoms, such as allergic rhinitis or chronic bronchitis, which, in the investigator's opinion, would confound interpretation of symptoms ratings for the acute respiratory infection;

• The Investigator will evaluate patients on twelve additional criteria for exclusion.